Back

Canagliglozin extends life span and leads to less weight gain in C57BL6 male mice

Habeos, E. E.; Filippopoulou, F.; Kanakis, M.; Habeos, G. I.; Lagoumintzis, G.; Taraviras, S.; Chartoumpekis, D. V.

2022-11-20 physiology
10.1101/2022.11.20.517248 bioRxiv
Show abstract

SGLT2 inhibitors are widely prescribed drugs for type 2 diabetes and heart failure. It seems that their beneficial health effects are multifaceted and not only limited to the amelioration of glycemic profile. It is suggested that SGLT2 inhibitors-induced glycosuria causes a metabolic shift that mimics the fasting response. It is also known that calorie restriction leads to enhanced longevity in mice. Thus, we hypothesized that long-term treatment of mice with SGLT2 inhibitors might extend their life span. To this end male C57BL6 mice at the age of 4 months were put on a normal chow diet or on a diet supplemented with 200 mg/kg canagliflozin. The canagliflozin-treated mice showed lower body weight gain over time and increased life span. The median survival of control mice was 107.5 weeks, while that of the canagliflozin-treated group was 112.5 weeks (p=0.011). No difference was seen in the presence or severity of cataracts. This study showed for the first time an enhanced median survival of canagliflozin-treated male mice with a homogeneous genetic background (C57BL6). Further analyses are in progress to elucidate the metabolic adaptations and mechanisms underlying this effect.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
PLOS ONE
● 5266 papers in training set
Top 2%
41.6%
Similar papers in this journal
2
Aging
○ 75 papers in training set
Top 0.2%
5.8%
Similar papers in this journal
3
Scientific Reports
○ 3612 papers in training set
Top 20%
4.6%
Similar papers in this journal
50% of probability mass above
4
GeroScience
○ 109 papers in training set
Top 0.5%
4.5%
Similar papers in this journal
5
International Journal of Molecular Sciences
○ 494 papers in training set
Top 4%
2.9%
Similar papers in this journal
6
Molecules
○ 39 papers in training set
Top 0.5%
2.2%
7
Cureus
○ 68 papers in training set
Top 2%
2.2%
8
Journal of Alzheimer’s Disease
○ 50 papers in training set
Top 0.6%
2.0%
9
FASEB BioAdvances
○ 18 papers in training set
Top 0.1%
1.8%
10
Life Sciences
○ 27 papers in training set
Top 0.5%
1.6%
11
Frontiers in Physiology
○ 106 papers in training set
Top 1%
1.6%
12
Cells
○ 249 papers in training set
Top 3%
1.5%
13
FEBS Open Bio
○ 31 papers in training set
Top 0.4%
1.2%
14
Biochemical and Biophysical Research Communications
○ 84 papers in training set
Top 1%
1.2%
15
Current Developments in Nutrition
○ 15 papers in training set
Top 0.5%
1.1%
16
Diabetes Research and Clinical Practice
○ 11 papers in training set
Top 0.2%
1.0%
17
eLife
● 5828 papers in training set
Top 64%
1.0%
18
Nutrients
○ 67 papers in training set
Top 2%
0.9%
19
The Journal of Steroid Biochemistry and Molecular Biology
○ 11 papers in training set
Top 0.2%
0.9%
20
Physiological Reports
○ 40 papers in training set
Top 1%
0.9%
21
Bioscience Reports
● 27 papers in training set
Top 1%
0.9%
22
Gene
○ 46 papers in training set
Top 2%
0.5%
23
Frontiers in Pharmacology
○ 111 papers in training set
Top 4%
0.5%
24
Pharmaceuticals
○ 34 papers in training set
Top 2%
0.5%
25
Journal of Personalized Medicine
○ 28 papers in training set
Top 2%
0.5%
26
Biochemical Pharmacology
○ 20 papers in training set
Top 0.6%
0.5%
27
Biochemistry and Biophysics Reports
○ 30 papers in training set
Top 2%
0.5%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.